NCT02051257View on ClinicalTrials.gov

Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 19, 2014

Primary Completion Date

March 8, 2026

Study Completion Date

March 8, 2026

Conditions
Recurrent Diffuse Large B-Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Mantle Cell LymphomaTransformed Recurrent Non-Hodgkin Lymphoma
Interventions
BIOLOGICAL

Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells

Given IV

BIOLOGICAL

Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER